The RSV Prevention Market: Expanding Horizons for High-Risk Children
The respiratory syncytial virus (RSV) prevention market is experiencing a significant shift, expanding its focus beyond infants entering their first RSV season to include high-risk children under the age of two entering their second season. This evolution in the market is driven by the understanding that RSV infection rates are alarmingly high, with over 90% of children contracting the virus before their second birthday. Infants younger than six months are particularly vulnerable, as the infection can lead to severe lower respiratory tract illnesses, often requiring hospitalization.
The global market for RSV prevention options is projected to grow exponentially, reaching a staggering $28.39 billion by 2030, with a compound annual growth rate (CAGR) of 42.17%. This rapid growth is a testament to the increasing demand for effective prevention strategies.
In Korea, the landscape is particularly intriguing. Sanofi's Beyfortus (nirsevimab) and MSD's Enflonsia (clesrovimab) are the first preventive antibodies approved for all newborns and infants entering their first RSV season. However, Beyfortus stands out as the only product approved for high-risk children under two years of age entering their second season. This is a crucial development, as it provides a more comprehensive solution for vulnerable populations.
High-risk children include those with chronic lung disease, congenital heart disease, compromised immune systems, or other conditions deemed high-risk by physicians. For these patients, an additional dose before the second RSV season is recommended, even after receiving protection during the first season. Until now, Synagis (palivizumab) has been the go-to option, but its five monthly injections during the RSV season made it less convenient for patients and caregivers.
Beyfortus offers a more convenient and effective solution, providing protection throughout the entire RSV season with a single injection. The U.S. Centers for Disease Control and Prevention (CDC) recommends Beyfortus for eligible high-risk children, further solidifying its importance in the field. The product has received authorization from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), and its effectiveness is supported by over 50 studies and real-world evidence involving more than 400,000 infants.
The impact of RSV preventive antibodies in Korea is already evident. According to the Korea Disease Control and Prevention Agency (KDCA) sentinel surveillance data, infant hospitalizations during the 2024-2025 RSV season peaked at 191 cases in epidemiological week 52 of 2024. In the subsequent season, following the introduction of Beyfortus, the peak was significantly reduced to 79 cases in epidemiological week 48. While these figures do not establish causality, they have drawn attention among clinicians.
Clinicians emphasize the importance of a dual approach to RSV prevention: universal protection for infants entering their first season and additional measures for high-risk children. Professor Choe Young-june of the Department of Pediatrics at Korea University Anam Hospital highlights the critical nature of prevention, as there is no effective treatment for RSV. He stresses the need for comprehensive preventive management, especially for high-risk children with underlying lung disease, heart disease, or immunocompromised conditions.
The introduction of RSV preventive antibodies in Korea has led to a meaningful reduction in infant hospitalizations, as noted by Professor Choe. This success story underscores the potential for a future where all newborns, infants, and high-risk children can be protected against RSV without financial barriers. As the market continues to evolve, the focus on high-risk children entering their second season is a crucial step towards a more comprehensive and effective RSV prevention strategy.
